Selection of oral antifungals for initial maintenance therapy in chronic pulmonary aspergillosis: A longitudinal analysis.
There is limited data for direct comparisons of the efficacy of oral itraconazole (ITCZ) and oral voriconazole (VRCZ) therapy in the treatment of chronic pulmonary aspergillosis (CPA). We conducted a retrospective follow-up observational study of CPA patients enrolled in two previous multicenter trials. Of the 273 CPA patients, 59 and 101 patients started maintenance therapy with oral ITCZ and oral VRCZ, respectively, just after the end of acute intravenous therapy in each trial. At the end of the observation period in this follow-up study (median observation period: 731 days), the percentage of patients showing improvement was lower in the ITCZ group than in the VRCZ group (18.2% vs. 40.0%); however, after including stable patients, the percentages were 50.9% and 52.6%, respectively, in the ITCZ and VRCZ groups, which were not significantly different (P=0.652). Multivariable Cox regression analysis showed no significant influence of the choice of initial maintenance treatment (ITCZ or VRCZ) on overall mortality as well as CPA-associated mortality. Multivariable logistic regression showed that oral ITCZ selection for initial maintenance therapy was an independent risk factor for hospital readmission and switching to other antifungal agents (odds ratio [OR] 3.1, 95% confidence interval [CI] 1.3-7.5; OR 5.7, 95% CI 2.0-15.7, respectively). Oral VRCZ for initial maintenance therapy showed better effectiveness than oral ITCZ for clinical improvement in CPA patients. On the other hand, there was no difference in crude mortality between initial maintenance therapy with VRCZ and ITCZ, especially in elderly CPA patients.